nach oben

Indian Journal of Surgery

Erschienen in:

30.10.2015 | Review Article

Hurthle Cell Lesion: Controversies, Challenges, and Debates

verfasst von: Michael Shawky, Mahmoud Sakr

Erschienen in: Indian Journal of Surgery | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Hurthle cell lesion is one of the most questionable clinico-pathological entities in most of its aspects. Literature has used the terms oncocytic, oxyphilic, Hurthle, and Ashkanazy interchangeably; what does each term denote? Who first described these cells? What is the cell of origin? How much Hurthle cells should be present to define the lesion as Hurthle cell one? Is it possible to differentiate hyperplastic from neoplastic and benign from malignant Hurthle cell lesion on a non-histopathologic ground? Does it belong to follicular or to papillary neoplasms or should it be classified separately? Can we anticipate its clinical behavior or predict its outcome? How can we manage? We will try to answer these questions in light of the ongoing relevant arguments with the aim of resolving some uncertainties and suggesting how to solve others.

Wakely PE Jr (2008) Oncocytic and oncocyte-like lesions of the head and neck. Ann Diagn Pathol 12(3):222–230PubMedCrossRef

Kontaxis A, Zanarotti U, Kainz J, Beham A (2004) Die diffuse Onkozytose der Glandula Parotidea. Laryngo-Rhino-Otologie 83(03):185–188PubMedCrossRef

Prabakaran SS, Chen F, Aguirre A (2010) Oncocytoma of the parotid gland and its mimickers: a comprehensive review. N Am J Med Sci 3:171–180CrossRef

Mete O, Asa SL (2010) Oncocytes, oxyphils, Hurthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules. Endocr Pathol 21(1):16–24PubMedCrossRef

Hurthle K (1894) BeitrÃgezurKenntniss des Secretionsvorgangs in der. SchilddrÃse. Pflugers Arch Physiol 56:10–44CrossRef

Ashkanazy M (1898) Pathologisch-anatomischeBeitrÃgezurKenntniss des. MorbusBasedowii, insbesondere Ã¼ber die dabeiauftretendeMuskelerkrankung. Dtsch Arch Klin Med 61:118–186

Johnson TL, Lloyd RV, Burney RE, Thompson NW (1987) Hurthle cell thyroid tumors. An immunohistochemical study. Cancer 59(1):107–112PubMedCrossRef

Clark OH, Gerend PL (1985) Thyrotropin receptor-adenylate cyclase system in Hurthle cell neoplasms. J Clin Endocrinol Metab 61(4):773–778PubMedCrossRef

Chen H, Udelsman R (2005) Chapter 14 - Hürthle cell adenoma and carcinoma. In: Kebebew OHC-YD (ed) Textbook of endocrine surgery, 2nd edn. W.B. Saunders, Philadelphia, pp 123–128CrossRef

10.

Evans HL, Vassilopoulou-Sellin R (1998) Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. Am J Surg Pathol 22(12):1512–1520PubMedCrossRef

11.

Sanders LE, Silverman M (1998) Follicular and Hürthle cell carcinoma: predicting outcome and directing therapy. Surgery 124(6):967–974PubMedCrossRef

12.

Masood S, Auguste L-J, Westerband A et al (1993) Differential oncogenic expression in thyroid follicular and Hürthle cell carcinomas. Am J Surg 166(4):366–368PubMedCrossRef

13.

Stankov K, Romeo G (2003) Oxyphilic carcinoma of the thyroid gland. Arch Oncol 11(2):81–89CrossRef

14.

Rosai J, Kuhn E, Carcangiu ML (2006) Pitfalls in thyroid tumour pathology. Histopathology 49(2):107–120PubMedCrossRef

15.

Asa S (2004) My approach to oncocytic tumours of the thyroid. J Clin Pathol 57(3):225–232PubMedPubMedCentralCrossRef

16.

Kroeker T, Prisman E, Shah M et al (2014) Hurthle cell lesions-a retrospective review of final surgical pathology. Thyroid Disord Ther 3(155):2

17.

Elliott DD, Pitman MB, Bloom L, Faquin WC (2006) Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: a cytomorphologic study of 139 cases with statistical analysis. Cancer 108(2):102–109PubMedCrossRef

18.

Barnabei A, Ferretti E, Baldelli R et al (2009) Hurthle cell tumours of the thyroid. Personal experience and review of the literature. Acta Otorhinolaryngol Ital 29(6):305–311PubMedPubMedCentral

19.

McHenry CR, Thomas SR, Slusarczyk SJ, Khiyami A (1999) Follicular or Hu ̈rthle cell neoplasm of the thyroid: can clinical factors be used to predict carcinoma and determine extent of thyroidectomy? Surgery 126(4):798–804PubMedCrossRef

20.

Pisanu A, Di Chiara B, Reccia I, Uccheddu A (2010) Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes. World J Surg 34(4):836–843PubMedCrossRef

21.

Yang YJ, Khurana KK (2001) Diagnostic utility of intracytoplasmic lumen and transgressing vessels in evaluation of Hurthle cell lesions by fine-needle aspiration. Arch Pathol Lab Med 125(8):1031–1035PubMed

22.

Lee KH, Shin JH, Ko ES et al (2013) Predictive factors of malignancy in patients with cytologically suspicious for Hurthle cell neoplasm of thyroid nodules. Int J Surg 11(9):898–902PubMedCrossRef

23.

Mills SC, Haq M, Smellie WJ, Harmer C (2009) Hurthle cell carcinoma of the thyroid: retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol 35(3):230–234PubMedCrossRef

24.

Hoos A, Stojadinovic A, Singh B et al (2002) Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol 160(1):175–183PubMedPubMedCentralCrossRef

25.

Maizlin ZV, Wiseman SM, Vora P et al (2008) Hurthle cell neoplasms of the thyroid: sonographic appearance and histologic characteristics. J Ultrasound Med 27(5):751–757, quiz 9 PubMed

26.

Cannon J (2011) The significance of Hürthle cells in thyroid disease. Oncologist 16(10):1380–1387PubMedPubMedCentralCrossRef

27.

Melck A, Bugis S, Baliski C et al (2006) Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. Am J Surg 191(5):593–597PubMedCrossRef

28.

Chao T-C, Lin J-D, Chen M-F (2005) Surgical treatment of Hurthle cell tumors of the thyroid. World J Surg 29(2):164–168PubMedCrossRef

29.

Chen H, Nicol TL, Zeiger MA et al (1998) Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg 227(4):542–546PubMedPubMedCentralCrossRef

30.

Hudak K, Mazeh H, Sippel RS, Chen H (2012) Hürthle cell metaplasia on fine-needle aspiration biopsy is not by itself an indication for thyroid surgery. Am J Surg 203(3):287–291PubMedCrossRef

31.

Montone KT, Baloch ZW, LiVolsi VA (2008) The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med 132(8):1241–1250PubMed

32.

Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214PubMedCrossRef

33.

Pu RT, Yang J, Wasserman PG et al (2006) Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol 34(5):330–334PubMedCrossRef

34.

Alaedeen DI, Khiyami A, McHenry CR (2005) Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease. Surgery 138(4):650–657PubMedCrossRef

35.

Galera-Davidson H, González-Cámpora R (2008) Chapter 23 - thyroid. In: Wilbur MB (ed) Comprehensive cytopathology, 3rd edn. W.B. Saunders, Edinburgh, pp 633–670CrossRef

36.

Clark D, Faquin W (2010) Hurthle cell lesions. Thyroid cytopathology. Springer, US, pp 93–107

37.

Kasper K, Stewart J III, Das K (2012) Fine needle aspiration cytology of thyroid nodules with Hürthle cells: cytomorphologic predictors for neoplasms, improving diagnostic accuracy and overcoming pitfalls. J Am Soc Cytopathol 1(1):S62–S63CrossRef

38.

Baloch ZW, LiVolsi VA, Asa SL et al (2008) Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 36(6):425–437PubMedCrossRef

39.

Chiappetta G, Toti P, Cetta F et al (2002) The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 87(1):364–369PubMedCrossRef

40.

Zhang YW, Greenblatt DY, Repplinger D et al (2008) QS264. Factors that predict malignancy in Hürthle cell neoplasms of the thyroid. J Surg Res 144(2):371–372CrossRef

41.

Stojadinovic A, Ghossein RA, Hoos A et al (2001) Hurthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol 19(10):2616–2625PubMed

42.

Pisanu A, Sias L, Uccheddu A (2004) Factors predicting malignancy of Hürthle cell tumors of the thyroid: influence on surgical treatment. World J Surg 28(8):761–765PubMedCrossRef

43.

Lopez-Penabad L, Chiu AC, Hoff AO et al (2003) Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97(5):1186–1194PubMedCrossRef

44.

Zhang Y, Greenblatt D, Repplinger D et al (2008) Older age and larger tumor size predict malignancy in Hürthle cell neoplasms of the thyroid. Ann Surg Oncol 15(10):2842–2846PubMedCrossRef

45.

Suh I, Vriens MR, Guerrero MA et al (2010) Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Ḧurthle-cell neoplasms of the thyroid. Am J Surg 200(1):41–46PubMedCrossRef

46.

Parikh PP, Allan BJ, Lew JI (2013) Surgeon-performed ultrasound predictors of malignancy in patients with Hürthle cell neoplasms of the thyroid. J Surg Res 184(1):247–252PubMedCrossRef

47.

Sugino K, Ito K, Mimura T et al (2001) Hürthle cell tumor of the thyroid: analysis of 188 cases. World J Surg 25(9):1160–1163PubMedCrossRef

48.

Sippel RS, Elaraj DM, Khanafshar E et al (2008) Tumor size predicts malignant potential in Hurthle cell neoplasms of the thyroid. World J Surg 32(5):702–707PubMedCrossRef

49.

Paunovic I, Krgovic K, Tatic S et al (2006) Surgery for thyroid Hürthle cell tumours—a single institution experience. Eur J Surg Oncol 32(4):458–461PubMedCrossRef

50.

Petric R, Besic H, Besic N (2014) Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hürthle cell neoplasms of the thyroid gland. World J Surg Oncol 12(1):1–7CrossRef

51.

Arduc A, Dogan BA, Tuna MM, et al (2015) Higher body mass index and larger waist circumference may be predictors of thyroid carcinoma in patients with Hurthle-cell lesion/neoplasm fine-needle aspiration diagnosis. Clin Endocrinol (Oxf) 83(3):405–411

52.

Erickson LA, Jin L, Goellner JR et al (2000) Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol 13(2):186–192PubMedCrossRef

53.

Cheung CC, Ezzat S, Ramyar L et al (2000) Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85(2):878–882PubMed

54.

Histopathology A (2004) Histopathology of thyroid tumors. An overview. Hormones 3(2):100–110CrossRef

55.

Berho M, Suster S (1997) The oncocytic variant of papillary carcinoma of the thyroid: a clinicopathologic study of 15 cases. Hum Pathol 28(1):47–53PubMedCrossRef

56.

Sabino de Matos P (2008) Thyroid epithelial tumours. Diagn Histopathol 14(5):236–246CrossRef

57.

Lloyd RV, Buehler D, Khanafshar E (2011) Papillary thyroid carcinoma variants. Head Neck Pathol 5(1):51–56PubMedPubMedCentralCrossRef

58.

Belchetz G, Cheung CC, Freeman J et al (2002) Hürthle cell tumors: using molecular techniques to define a novel classification system. Arch Otolaryngol Head Neck Surg 128(3):237–240PubMedCrossRef

59.

Musholt PB, Imkamp F, von Wasielewski R et al (2003) RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hürthle cell carcinomas? Surgery 134(6):881–889PubMedCrossRef

60.

Nikiforov YE, Biddinger PW, Thompson LDR (2012) Diagnostic pathology and molecular genetics of the thyroid: a comprehensive guide for practicing thyroid pathology. USA, Wolters Kluwer Health

61.

Haigh PI, Urbach DR (2005) The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. Surgery 138(6):1152–1158PubMedCrossRef

62.

Khafif A, Khafif RA, Attie JN (1999) Hürthle cell carcinoma: a malignancy of low-grade potential. Head Neck 21(6):506–511PubMedCrossRef

63.

Kushchayeva Y, Duh Q-Y, Kebebew E et al (2008) Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg 195(4):457–462PubMedCrossRef

64.

Dettori T, Frau DV, Lai ML et al (2003) Aneuploidy in oncocytic lesions of the thyroid gland: diffuse accumulation of mitochondria within the cell is associated with trisomy 7 and progressive numerical chromosomal alterations. Genes Chromosom Cancer 38(1):22–31PubMedCrossRef

65.

Wada N, Duh QY, Miura D et al (2002) Chromosomal aberrations by comparative genomic hybridization in hurthle cell thyroid carcinomas are associated with tumor recurrence. J Clin Endocrinol Metab 87(10):4595–4601PubMedCrossRef

66.

Máximo V, Soares P, Lima J et al (2002) Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol 160(5):1857–1865PubMedPubMedCentralCrossRef

67.

Carcangiu ML, Bianchi S, Savino D et al (1991) Follicular Hurthle cell tumors of the thyroid gland. Cancer 68(9):1944–1953PubMedCrossRef

68.

Finley DJ, Zhu B, Fahey Iii TJ (2004) Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 136(6):1160–1168PubMedCrossRef

69.

Chindris A-M, Casler JD, Bernet VJ, et al (2014) Clinical and molecular features of Hürthle cell carcinoma of the thyroid. J Clin Endocrinol Metab 0(0):jc.2014-1634

70.

Papotti M, Torchio B, Grassi L et al (1996) Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol 20(6):686–694PubMedCrossRef

71.

Dedivitis RA, Di Giovanni JH, Silva GF et al (2004) Oncocytic variant of medullary thyroid carcinoma: case report. Arq Bras Endocrinol Metabol 48(2):315–317PubMedCrossRef

72.

Sobrinho-Simões M, Magalhães J, Fonseca E, Amendoeira I (2005) Diagnostic pitfalls of thyroid pathology. Curr Diagn Pathol 11(1):52–59CrossRef

73.

Ain K (2000) Unusual types of thyroid cancer. Rev Endocr Metab Disord 1(3):225–231PubMedCrossRef

74.

Bhattacharyya N (2003) Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg 129(2):207–210PubMedCrossRef

75.

Ozlem Kucuk N, Kulak H, Tokmak E et al (2006) Hurthle cell carcinoma: a clinicopathological study of thirteen cases. Nucl Med Commun 27(4):377–379PubMedCrossRef

76.

Yutan E, Clark O (2001) Hürthle cell carcinoma. Curr Treat Options in Oncol 2(4):331–335CrossRef

77.

Shaha AR, Shah JP, Loree TR (1996) Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 172(6):692–694PubMedCrossRef

78.

Ruegemer JJ, Hay ID, Bergstralh EJ et al (1988) Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67(3):501–508PubMedCrossRef

79.

Schneider DF, Chen H (2013) New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin 63(6):373–394PubMedCentralCrossRef

80.

Shaha AR, Loree TR, Shah JP (1995) Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118(6):1131–1138PubMedCrossRef

81.

Herrera M, Hay I, Wu PC et al (1992) Hürthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg 16(4):669–674PubMedCrossRef

82.

McDonald MP, Sanders LE, Silverman ML et al (1996) Hürthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery 120(6):1000–1005PubMedCrossRef

83.

Stojadinovic A, Hoos A, Ghossein R et al (2002) Hürthle cell carcinoma: a 60-year experience. Ann Surg Oncol 9(2):197–203PubMed

84.

Goldstein NS, Czako P, Neill JS (2000) Metastatic minimally invasive (encapsulated) follicular and Hurthle cell thyroid carcinoma: a study of 34 patients. Mod Pathol 13(2):123–130PubMedCrossRef

85.

Azadian A, Rosen IB, Walfish PG, Asa SL (1995) Management considerations in Hürthle cell carcinoma. Surgery 118(4):711–715PubMedCrossRef

86.

Kauffmann PR, Dejax C, de Latour M, Dauplat J (2004) The meaning and predictivity of Hürthle cells in fine needle aspiration cytology for thyroid nodular disease. Eur J Surg Oncol 30(7):786–789PubMedCrossRef

87.

Gallagher L, Hughes M, McMillian L (2013) National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Thyroid Carcinoma Version 2. 2013. Available from: http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf

88.

Alexander EK, Kennedy GC, Baloch ZW et al (2012) Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367(8):705–715PubMedCrossRef

89.

Tuzun D, Ersoy R, Kilicyazgan A, et al (2014) Elastosonography scoring and strain index of thyroid nodules with Hurthle cells. Minerva Endocrinol [Epub ahead of print]

Titel: Hurthle Cell Lesion: Controversies, Challenges, and Debates
verfasst von: Michael Shawky
Mahmoud Sakr
Publikationsdatum: 30.10.2015
Verlag: Springer India
Erschienen in: Indian Journal of Surgery / Ausgabe 1/2016
Print ISSN: 0972-2068
Elektronische ISSN: 0973-9793
DOI: https://doi.org/10.1007/s12262-015-1381-x

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Longitudinal Pancreatico-Jejunostomy Vs lateral Pancreatico-Gastrostomy as a Drainage Procedure for Pain Relieve in Chronic Pancreatitis Done in a Tertiary Referral Centre of Eastern India

A Review on the History of ‘Thyroid Surgery’

Evaluation of Factors Affecting the Type of Gallstone

Rational Hyperoxia in the Perioperative Period: a Safe and Effective Tool in the Reduction of SSI

Extraosseous Ewing Sarcoma: Diagnosis, Prognosis and Optimal Management

Mass in the Left Iliac Fossa—a Diagnostic Dilemma

Update Chirurgie